The University of Yamagata, Japan, announced on Friday that the drug, which is being developed for the treatment of Alzheimer’s disease, has been shown to be effective in treating amyotrophic lateral sclerosis, commonly known as Lu Gherig’s disease.
The drug has the potential to prevent abnormal proteinuria caused by progressive neurodegenerative disease, according to a government university in northeastern Japan.
People with ALS lose the ability to walk, talk, eat, and breathe because the disease kills motor neurons, weakens the muscles, and eventually paralyzes them.
Amyotrophic lateral sclerosis patient (C) will receive home care in Fukushima Province, Japan in November 2020. (Kyodo)
“There are drugs that can slow the progression of the disease, but the new drug under construction will be the first of its kind to work on proteins stored in the brain and spinal cord,” said Tacoo Kato, head of the YamSata National Hospital ALS. Medical Research Center.
Deadly disease is characterized by the proliferation of damaged proteins in damaged motor neurons, but the research team managed to inhibit protein synthesis by administering the drug to a laboratory-developed ALS.
Since the experiments were performed on mice suffering from family ALS, the rare type, researchers now perform experiments on rare or non-inherited mice.
The research team It aims to launch clinical trials involving human patients by 2024.
There are about 10,000 people suffering from Alzheimer’s in Japan, and between 1,000 and 2,000 people get new infections every year, says Mitsubishi Tanabe Pharma Corp.
Alzheimer’s disease, the most common cause of Alzheimer’s disease, is thought to be caused by a buildup of beta-amyloid protein and twisted fiber in the brain’s tau protein, according to the Alzheimer’s Association.
Attention: Health experts say the death of an ALS woman in Kyoto is not a matter of Euthanasia
In Japan, the disabled legislator uses speech interference in the 1st
The cafe will be opened by robot hosts remotely controlled by people with disabilities.